Celmatix Launches Novel Endometriosis Drug Program
NEW YORK–(BUSINESS WIRE)–Celmatix Therapeutics, a biotechnology company focused on advancing groundbreaking therapeutics for women’s health, has announced its latest drug program, a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The therapeutic drug candidate, developed using the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery, Baylor College of Medicine (BCM), aims to address a critical unmet need in first-line treatments